There is a shortage of subsidized medicines in hospital pharmacies, Kommersantwrites . This became known as a result of a survey of doctors, who conducted the service "Action Medicine". The purpose of the survey was to find out the attitude of doctors to the May decree of Prime Minister Mikhail Mishustin on the issuance of expired medicines to beneficiaries in order to make up for part of their shortage, which may arise due to sanctions.

The study involved 300 health workers of various specializations. 78% of respondents indicated that their medical facility has deteriorated drug supply. Difficulties with expensive drugs costing more than 700 rubles are observed in every third organization. 31% of the respondents said that there was a shortage of medicines worth 200-700 rubles. Every tenth clinic has difficulties with cheap medicines worth 200 rubles.

75% of respondents confirmed that in their medical institution, patients receive preferential drugs. A third of doctors indicated that such patients are from 15% to 20%. 40% of respondents believe that the transfer of drugs with an expiring shelf life will worsen the situation of patients. In their opinion, Kommersant writes, many citizens stock up for several months and then take expired medicines. 60% of respondents believe that "nothing terrible happened."

Among the medicines that are most lacking, the respondents named:

• antiepileptic drugs,
• drugs that lower blood pressure (hypotensive),
• insulins and hypoglycemic agents,
• "foreign effective" psychotropic drugs,
• drugs for the treatment of thyroid diseases.

Some respondents indicated that their medical institutions do not have “practically all medicines for children at a discount”, and “regional programs lack everything: diabetic, antihypertensive, anti-asthma medicines”. The survey included an answer about the anti-tuberculosis drug delamanide, which is "introduced into treatment regimens by clinical guidelines, but in fact it is not."

This is not the first problem that the Russian pharmaceutical industry has faced since the start of the war. In May, the head of the scientific expertise of the pharmaceutical venture fund Inbio Ventures, Ilya Yasny, in a conversation with The Insider, said that Russia was running out of reagents for laboratory tests, and problems were coming with the production of medicines and disinfectants, in particular hydrogen peroxide.

In June, Kommersant wrote that Russia also faced a shortage of control equipment - chromatographic columns, which are needed to develop new drugs and control the quality of old ones.

At the same time, the head of the Russian Ministry of Health, Mikhail Murashko, stated on June 1 that “we are not experiencing any difficulties with regard to medicines today.”